Company Profiles
-
Breethe, Inc.
Breethe, Inc. is a product development-stage company spun out of the University of Maryland, Baltimore in 2014 to develop and commercialize the world's first wearable artificial lung.
[ Visit Website ]
Category:Devices
Established:
-
Cook Medical
Cook Medical makes 16,000 products that serve 13 hospital lines and provides products to 135 countries.
[ Visit Website ]
Category:Devices
-
Countervail Corporation
Countervail Corporation is focused on providing protection and treatment of military and civilian populations from exposure to chemical and biological weapons.
[ Visit Website ]
Category:Biologics
Established:
-
PaxVax
PaxVax is an independent vaccine company with a robust pipeline that brings to market specialty vaccines that protect against existing and emerging infectious diseases.
[ Visit Website ]
Category:Vaccines
Established:
-
Archimedes Bioengineering, LLC
Archimedes Bioengineering, LLC is a collaborative effort between University of Maryland, College Park (UMCP), Children’s National Medical Center, and a private company. Archimedes is based on a portfolio of patent pending diagnostic technologies that enable the detection of aminoacidopathy disorders such as, Hyperammonemia, Phenylketonuria (PKU), Maple Syrup Urine Disease, and Aminoacidemia which are a group of metabolic disorders that result from the build-up of one or more amino acids in the blood and/or urine. These metabolic disorders may be caused by defects in enzymatic pathways that inhibit the metabolism of the certain amino acids. Using different diagnostic device designs and embodiments, Archimedes hopes to revolutionize the point-of-care market for aminoacidopathy diagnostics.
[ Visit Website ]
Category:Bioengineering
Established:
-
Otomagnetics, LLC
A University of Maryland College Park spin-out, is developing a non-invasive method to effectively deliver drugs and other therapeutic payloads to the inner and middle ear.
[ Visit Website ]
Category:Bioengineering
Established:
-
ElectroMed, LLC
ElectroMed, LLC has licensed the Quick-Release Self-Contained Medical Electrode (US Patent 8,897,853) developed by students at the Fischell Department of Bioengineering. This novel electrode achieves five goals in having increased hydrogel adhesiveness, combining the electrode and adhesive remover in a single unit, greatly reducing removal force required, eliminating leftover residue, and whose removal would not compromise local tissues in sensitive skin situations. These properties make the electrode ideal for burn victims and neonates as it strongly adheres to damaged and growing skin while not injuring delicate skin during removal
Category:Bioengineering
Established:
-
Sintact Medical Systems, Inc.
Sintact Medical Systems, Inc. develops non-resorbable films that separate adjacent organs from adhering to each other after surgery.
[ Visit Website ]
Category:Biomaterials
Established:
-
Rakta Therapeutics, Inc.
Rakta Therapeutics, Inc. has licensed the rights to a series of small molecules for the treatment of leishmaniasis, one of the World Health Organizations neglected tropical diseases. Spread by bites sandflies, the Leshmania protozoan are the cause of the disease. Leishmaniasis affects millions of people worldwide and results in tens of thousands of deaths each year. Previous research at the University of Maryland has identified that Leshmania were unable to synthesize heme, a molecule essential for cellular function. Since these protozoans cannot synthesize heme, the parasitic protozoan must absorb heme from their hosts. Through further collaboration with the University of Maryland, Baltimore, the researchers developed inhibitors of the Leshmania heme transport mechanism. Rakta Therapeutics has licensed these inhibitors with the goal of developing the compounds into effective treatments for leishmaniasis.
Category:Small molecules
Established:
-
Calabash Biosciences
Calabash Biosciences is based on a technology that uses novel molecular containers for efficient drug delivery applications. These molecular containers first conceived and created by University of Maryland’s (UMCP) investigators improve the solubilization of drugs and allow them to be easily accessed by the body. The enhanced solubilization makes them superior to the currently available cyclodextrixn class of compounds. Calabash was initiated as a follow-up to collaborative research efforts between investigators at the UMCP and Mass General Hospital. Their collaboration involved the study of drug solubilization applications, in particular, the reversal of neuromuscular blocking (NMB) or anesthesia inducing agents. Calabash is in the process of developing new formulations for a variety of currently available drugs in the market.
Category:Small molecules
Established: